The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing
Open accessAbstract
New HIV therapies are urgently needed to address the growing problem of drug resistance. In this article, we characterize the anti-HIV drug candidate 3- O -(3′,3′-dimethylsuccinyl) betulinic acid (PA-457). We show that PA-457 potently inhibits replication of both WT and drug-resistant HIV-1 isolates and demonstrate that the compound acts by disrupting a late step in Gag processing involving conversion of the capsid precursor (p25) to mature capsid protein (p24). We find that virions from PA-457-treated cultures are noninfectious and exhibit an aberrant particle morphology characterized by a spherical, acentric core and a crescent-shaped, electron-dense shell lying just inside the viral membrane. To identify the determinants of compound activity we selected for PA-457-resistant virus in vitro . Consistent with the effect on Gag processing, we found that mutations conferring resistance to PA-457 map to the p25 to p24 cleavage site. PA-457 represents a unique class of anti-HIV compounds termed maturation inhibitors that exploit a previously unidentified viral target, providing additional opportunities for HIV drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adachi, A., Gendelman, H. E., Koenig, S., Folks, T., Willey, R., Rabson, A., & Martin, M. A. (1986) · Journal of Virology · doi:10.1128/jvi.59.2.284-291.1986 · Cited by 2,834
Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding
Garrus, J. E., von Schwedler, U. K., Pornillos, O. W., Morham, S. G., Zavitz, K. H., Wang, H. E., Wettstein, D. A., Stray, K. M., Côté, M., Rich, R. L., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00506-2 · Cited by 1,369
Antiretroviral-Drug Resistance among Patients Recently Infected with HIV
Little, S. J., Holte, S., Routy, J.-P., Daar, E. S., Markowitz, M., Collier, A. C., Koup, R. A., Mellors, J. W., Connick, E., Conway, B., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013552 · Cited by 1,140
Roehm, N. W., Rodgers, G. H., Hatfield, S. M., & Glasebrook, A. L. (1991) · Journal of Immunological Methods · doi:10.1016/0022-1759(91)90114-u · Cited by 1,012
Kimpton, J., & Emerman, M. (1992) · Journal of Virology · doi:10.1128/jvi.66.4.2232-2239.1992 · Cited by 908
HIV-1 Gag proteins: diverse functions in the virus life cycle
Freed, E. O. (1998) · Virology · doi:10.1006/viro.1998.9398 · Cited by 717
Self-citationMartin-Serrano, J., Zang, T., & Bieniasz, P. D. (2001) · Nature Medicine · doi:10.1038/nm1201-1313 · Cited by 710
Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release
Göttlinger, H. G., Dorfman, T., Sodroski, J. G., & Haseltine, W. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.8.3195 · Cited by 647
Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55 Gag
VerPlank, L., Bouamr, F., LaGrassa, T. J., Agresta, B., Kikonyogo, A., Leis, J., & Carter, C. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.131059198 · Cited by 584
Huang, M., Orenstein, J. M., Martin, M. A., & Freed, E. O. (1995) · Journal of Virology · doi:10.1128/jvi.69.11.6810-6818.1995 · Cited by 486
Self-citation
Cited by
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
HIV-1 Antiretroviral Drug Therapy
Arts, E. J., & Hazuda, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007161 · Cited by 851
Pharmacological activities of natural triterpenoids and their therapeutic implications
Dzubak, P., Hajduch, M., Vydra, D., Hustova, A., Kvasnica, M., Biedermann, D., Markova, L., Urban, M., & Sarek, J. (2006) · Natural Product Reports · doi:10.1039/b515312n · Cited by 708
HIV-1 assembly, release and maturation
Freed, E. O. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3490 · Cited by 654
Self-citationPharmacological properties of the ubiquitous natural product betulin
Alakurtti, S., Mäkelä, T., Koskimies, S., & Yli-Kauhaluoma, J. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.04.006 · Cited by 650
Moses, T., Papadopoulou, K. K., & Osbourn, A. (2014) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2014.953628 · Cited by 557
The structural biology of HIV assembly
Ganser-Pornillos, B. K., Yeager, M., & Sundquist, W. I. (2008) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2008.02.001 · Cited by 503
Natural products to drugs: natural product derived compounds in clinical trials
Butler, M. S. (2005) · Natural Product Reports · doi:10.1039/b402985m · Cited by 491
Plant-derived compounds in clinical trials
Saklani, A., & Kutty, S. K. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.010 · Cited by 477
The design of drugs for HIV and HCV
Clercq, E. D. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2424 · Cited by 430
The structural biology of HIV-1: mechanistic and therapeutic insights
Engelman, A., & Cherepanov, P. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2747 · Cited by 424
Antivirals and antiviral strategies
Clercq, E. D. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro975 · Cited by 370
Birch bark research and development
Krasutsky, P. A. (2006) · Natural Product Reports · doi:10.1039/b606816b · Cited by 337
Electron cryotomography of immature HIV‐1 virions reveals the structure of the CA and SP1 Gag shells
Wright, E. R., Schooler, J. B., Ding, H. J., Kieffer, C., Fillmore, C., Sundquist, W. I., & Jensen, G. J. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601664 · Cited by 325
“DSB inhibits maturation by blocking Gag cleavage at the CA–SP1 junction, and point mutations in residues surrounding this junction can confer drug resistance (Kanamoto et al, 2001; Li et al, 2003; Zhou et al, 2004, 2005; Aiken and Chen, 2005; Yu et al, 2005).”
InfluentialHIV drug development: the next 25 years
Flexner, C. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2336 · Cited by 317
HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention
Blair, W. S., Pickford, C., Irving, S. L., Brown, D. G., Anderson, M., Bazin, R., Cao, J., Ciaramella, G., Isaacson, J., Jackson, L., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001220 · Cited by 291
Lee, K.-H. (2010) · Journal of Natural Products · doi:10.1021/np900821e · Cited by 278
Betulin and its derivatives as novel compounds with different pharmacological effects
Amiri, S., Dastghaib, S., Ahmadi, M., Mehrbod, P., Khadem, F., Behrouj, H., Aghanoori, M.-R., Machaj, F., Ghamsari, M., Rosik, J., et al. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.06.008 · Cited by 272
Human immunodeficiency virus type 1 assembly, release, and maturation
Adamson, C. S., & Freed, E. O. (2007) · Advances in Pharmacology · doi:10.1016/s1054-3589(07)55010-6 · Cited by 179
Self-citationRetroviral proteases and their roles in virion maturation
Konvalinka, J., Kräusslich, H.-G., & Müller, B. (2015) · Virology · doi:10.1016/j.virol.2015.03.021 · Cited by 148
Structural Analysis of HIV-1 Maturation Using Cryo-Electron Tomography
de Marco, A., Müller, B., Glass, B., Riches, J. D., Kräusslich, H.-G., & Briggs, J. A. G. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001215 · Cited by 114
Fontana, J., Jurado, K. A., Cheng, N., Ly, N. L., Fuchs, J. R., Gorelick, R. J., Engelman, A. N., & Steven, A. C. (2015) · Journal of Virology · doi:10.1128/jvi.01522-15 · Cited by 96
Lee, S.-K., Harris, J., & Swanstrom, R. (2009) · Journal of Virology · doi:10.1128/jvi.00317-09 · Cited by 83
Structural and functional insights into the HIV-1 maturation inhibitor binding pocket
Waki, K., Durell, S. R., Soheilian, F., Nagashima, K., Butler, S. L., & Freed, E. O. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002997 · Cited by 71
Self-citationHydrogen/Deuterium Exchange Analysis of HIV-1 Capsid Assembly and Maturation
Monroe, E. B., Kang, S., Kyere, S. K., Li, R., & Prevelige, P. E. (2010) · Structure · doi:10.1016/j.str.2010.08.016 · Cited by 49
Adamson, C. S., Waki, K., Ablan, S. D., Salzwedel, K., & Freed, E. O. (2009) · Journal of Virology · doi:10.1128/jvi.02659-08 · Cited by 48
Self-citationIrregular and Semi‐Regular Polyhedral Models for Rous Sarcoma Virus Cores
Heymann, J. B., Butan, C., Winkler, D. C., Craven, R. C., & Steven, A. C. (2008) · Computational and Mathematical Methods in Medicine · doi:10.1080/17486700802168106 · Cited by 36
“The structures of helical tubes [26] and 2D crystals [19,22,30–33] of CA proteins established the”
Cyclic peptide inhibitors of HIV-1 capsid-human lysyl-tRNA synthetase interaction
Dewan, V., Liu, T., Chen, K.-M., Qian, Z., Xiao, Y., Kleiman, L., Mahasenan, K. V., Li, C., Matsuo, H., Pei, D., et al. (2012) · ACS Chemical Biology · doi:10.1021/cb200450w · Cited by 33
Structural basis of HIV-1 maturation inhibitor binding and activity
Sarkar, S., Zadrozny, K. K., Zadorozhnyi, R., Russell, R. W., Quinn, C. M., Kleinpeter, A., Ablan, S., Meshkin, H., Perilla, J. R., Freed, E. O., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36569-y · Cited by 28
Self-citationRecent advances in HIV-1 Gag inhibitor design and development
Dick, A., & Cocklin, S. (2020) · Molecules · doi:10.3390/molecules25071687 · Cited by 28
Metadata
- Authors
- Li, F., Goila-Gaur, R., Salzwedel, K., Kilgore, N. R., Reddick, M., Matallana, C., Castillo, A., Zoumplis, D., Martin, D. E., Orenstein, J. M., Allaway, G. P., Freed, E. O., & Wild, C. T.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2003-10-22
- Volume
- 100
- Issue
- 23
- Pages
- 13555-13560
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2132762790
- Cited by
- 426
- References
- 35
- FWCI
- 11.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.